Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Total Liabilities (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Total Liabilities data on record, last reported at $55.8 million in Q4 2025.

  • For Q4 2025, Total Liabilities rose 23.12% year-over-year to $55.8 million; the TTM value through Dec 2025 reached $55.8 million, up 23.12%, while the annual FY2025 figure was $55.8 million, 23.12% up from the prior year.
  • Total Liabilities reached $55.8 million in Q4 2025 per CLDX's latest filing, up from $50.1 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $55.8 million in Q4 2025 and bottomed at $21.8 million in Q2 2023.
  • Average Total Liabilities over 5 years is $32.4 million, with a median of $31.1 million recorded in 2024.
  • Peak YoY movement for Total Liabilities: skyrocketed 70.05% in 2022, then crashed 42.5% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $25.2 million in 2021, then grew by 5.37% to $26.5 million in 2022, then skyrocketed by 37.41% to $36.5 million in 2023, then increased by 24.36% to $45.3 million in 2024, then increased by 23.12% to $55.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $55.8 million in Q4 2025, $50.1 million in Q3 2025, and $37.0 million in Q2 2025.